18F-FDG PET/CT影像组学应用于淋巴瘤诊疗及预后预测的研究进展

doi:10.3969/j.issn.1674-8115.2023.06.016

上海交通大学学报（医学版） ›› 2023, Vol. 43 ›› Issue (6): 781-787.doi: 10.3969/j.issn.1674-8115.2023.06.016

• 综述 • 上一篇

¹⁸F-FDG PET/CT影像组学应用于淋巴瘤诊疗及预后预测的研究进展

程然(), 胡佳佳, 李彪()

上海交通大学医学院附属瑞金医院核医学科，上海 200025

收稿日期:2023-01-29 接受日期:2023-05-04 出版日期:2023-06-28 发布日期:2023-06-28
通讯作者: 李彪 E-mail:chengran354@163.com;lb10363@rjh.com.cn
作者简介:程然（1998—），女，博士生；电子信箱：chengran354@163.com。
基金资助:
上海市浦江人才计划（D类）(21PJD042);上海市“医苑新星”青年医学人才——医学影像项目;上海市临床重点专科建设项目(shslczdzk03403)

Advances in the application of ¹⁸F-FDG PET/CT radiomics for diagnosis, treatment and prognosis prediction of lymphoma

CHENG Ran(), HU Jiajia, LI Biao()

Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2023-01-29 Accepted:2023-05-04 Online:2023-06-28 Published:2023-06-28
Contact: LI Biao E-mail:chengran354@163.com;lb10363@rjh.com.cn
Supported by:
Shanghai Pujiang Program (Class D)(21PJD042);Shanghai Youth Medical Talents-Medical Imaging Practitioner Program;Project of Shanghai Key Clinical Specialty Construction(shslczdzk03403)

摘要/Abstract

摘要：

淋巴瘤是一种高度异质性的血液系统恶性肿瘤，全身各器官可受累，各亚型间临床特点存在很大差异。¹⁸F氟代脱氧葡萄糖（¹⁸F-fluorodeoxyglucose，¹⁸F-FDG）PET/CT是淋巴瘤临床诊断及治疗过程中重要的影像学检查方法，利于高侵袭性淋巴瘤的解剖学定位及代谢特征量化。该法通过比较治疗前后、病灶与血池的代谢变化从而系统评价疾病。但淋巴瘤异质性及¹⁸F-FDG PET/CT鉴别的局限性增加了医师的诊断难度，从而影响患者的临床治疗方案及预后。随着计算机硬件和图像分析技术的进步，基于提取病灶影像学特征进行分析诊断的影像组学技术应运而生。许多研究者投身于淋巴瘤¹⁸F-FDG PET/CT的影像组学研究，通过特征数据与相关临床数据结合建立模型，将图像信息、临床信息、病理及生存期等随访结果有效关联，提高了影像诊断的准确性和效率；同时根据模型预测预后和疗效，有望减少因医师经验差异导致的主观误差，辅助实现精准医疗。该文从诊断和鉴别诊断、预后预测和风险分级、药物疗效预测及影像组学分析算法优化等方面，对近年来¹⁸F-FDG PET/CT影像组学应用于淋巴瘤诊疗及预后评估的研究进展进行全面综述，以期为进一步研究机器学习、开发医学影像分析技术提供思路。

关键词: 影像组学, 淋巴瘤, 正电子发射断层显像, X射线计算机体层摄影, ¹⁸F氟代脱氧葡萄糖

Abstract:

Lymphoma is a highly heterogeneous hematological malignancy that can affect multiple organs throughout the body, exhibiting significant clinical variations among its subtypes. ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET/CT plays a crucial role in the clinical diagnosis and treatment of lymphoma by facilitating anatomical localization and quantification of metabolic characteristics of highly aggressive lymphomas. This imaging examination method enables a comprehensive evaluation by comparing the metabolic changes before and after treatment, as well as the metabolic difference between lesions and blood pools. However, the heterogeneity of lymphoma, coupled with the limitations of ¹⁸F-FDG PET/CT in differentiation, poses challenges for physicians and adversely impacts the clinical treatment plan and prognosis of patients. With the advancement of computer hardware and image analysis technology, radiomics technology, based on the extraction of imaging features of lesions for analysis and diagnosis, has emerged. Numerous researchers have dedicated their efforts to exploring imageomics in lymphoma assessment by using ¹⁸F-FDG PET/CT. By integrating feature data with relevant clinical information, models have been developed to effectively correlate image information, clinical data, pathology, and survival outcomes, thereby enhancing the accuracy and efficiency of imaging diagnosis. Furthermore, the utilization of predictive models for prognosis and treatment efficacy has the potential to mitigate subjective errors arising from disparities in physician experience, thereby contributing to the realization of personalized medicine. This review intends to comprehensively summarize the research progress of ¹⁸F-FDG PET/CT radiomics in the diagnosis, treatment and evaluation of lymphoma in recent years, from the aspects of diagnosis and differential diagnosis, prognosis prediction and risk grading, drug efficacy prediction and radiomics analysis algorithm optimization, so as to provide insights for future research in machine learning and the development of medical imaging analysis techniques.

Key words: radiomics, lymphoma, positron emission tomography, X-ray computed tomography, ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)

中图分类号:

R733.1

程然, 胡佳佳, 李彪. ¹⁸F-FDG PET/CT影像组学应用于淋巴瘤诊疗及预后预测的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(6): 781-787.

CHENG Ran, HU Jiajia, LI Biao. Advances in the application of ¹⁸F-FDG PET/CT radiomics for diagnosis, treatment and prognosis prediction of lymphoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(6): 781-787.

参考文献 39

1	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	LIU W P, LIU J M, SONG Y Q, et al. Burden of lymphoma in China, 1990—2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019[J]. Aging, 2022, 14(7): 3175-3190.
3	MILLER K D, NOGUEIRA L, DEVASIA T, et al. Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436.
4	CHESON B D, FISHER R I, BARRINGTON S F, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068.
5	BARRINGTON S F, KLUGE R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas[J]. Eur J Nucl Med Mol Imaging, 2017, 44(Suppl 1): S97-S110.
6	CHESON B D, MEIGNAN M. Current role of functional imaging in the management of lymphoma[J]. Curr Oncol Rep, 2021, 23(12): 144.
7	JIANG H, LI A, JI Z Y, et al. Role of radiomics-based baseline PET/CT imaging in lymphoma: diagnosis, prognosis, and response assessment[J]. Mol Imaging Biol, 2022, 24(4): 537-549.
8	CASALI M, LAURI C, ALTINI C, et al. State of the art of ¹⁸F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation[J]. Clin Transl Imaging, 2021, 9(4): 299-339.
9	MAYERHOEFER M E, MATERKA A, LANGS G, et al. Introduction to radiomics[J]. J Nucl Med, 2020, 61(4): 488-495.
10	VAN TIMMEREN J E, CESTER D, TANADINI-LANG S, et al. Radiomics in medical imaging-"how-to" guide and critical reflection[J]. Insights Imaging, 2020, 11(1): 91.
11	VISVIKIS D, CHEZE LE REST C, JAOUEN V, et al. Artificial intelligence, machine (deep) learning and radio(geno)mics: definitions and nuclear medicine imaging applications[J]. Eur J Nucl Med Mol Imaging, 2019, 46(13): 2630-2637.
12	DE JESUS F M, YIN Y, MANTZOROU-KYRIAKI E, et al. Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [¹⁸F]FDG PET/CT features[J]. Eur J Nucl Med Mol Imaging, 2022, 49(5): 1535-1543.
13	AIDE N, TALBOT M, FRUCHART C, et al. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2018, 45(5): 699-711.
14	MAYERHOEFER M E, UMUTLU L, SCHÖDER H. Functional imaging using radiomic features in assessment of lymphoma[J]. Methods, 2021, 188: 105-111.
15	MAYERHOEFER M E, RIEDL C C, KUMAR A, et al. [¹⁸F]FDG-PET/CT radiomics for prediction of bone marrow involvement in mantle cell lymphoma: a retrospective study in 97 patients[J]. Cancers, 2020, 12(5): 1138.
16	KONG Z R, JIANG C D, ZHU R Z, et al. ¹⁸F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma[J]. Neuroimage Clin, 2019, 23: 101912.
17	OU X J, ZHANG J, WANG J, et al. Radiomics based on ¹⁸F-FDG PET/CT could differentiate breast carcinoma from breast lymphoma using machine-learning approach: a preliminary study[J]. Cancer Med, 2020, 9(2): 496-506.
18	ZHU S, XU H, SHEN C Y, et al. Differential diagnostic ability of ¹⁸F-FDG PET/CT radiomics features between renal cell carcinoma and renal lymphoma[J]. Q J Nucl Med Mol Imaging, 2021, 65(1): 72-78.
19	SIBILLE L, SEIFERT R, AVRAMOVIC N, et al. ¹⁸F-FDG PET/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks[J]. Radiology, 2020, 294(2): 445-452.
20	LOVINFOSSE P, FERREIRA M, WITHOFS N, et al. Distinction of lymphoma from sarcoidosis on ¹⁸F-FDG PET/CT: evaluation of radiomics-feature-guided machine learning versus human reader performance[J]. J Nucl Med, 2022, 63(12): 1933-1940.
21	FROOD R, CLARK M, BURTON C, et al. Utility of pre-treatment FDG PET/CT-derived machine learning models for outcome prediction in classical Hodgkin lymphoma[J]. Eur Radiol, 2022, 32(10): 7237-7247.
22	AKHTARI M, MILGROM S A, PINNIX C C, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation[J]. Blood, 2018, 131(1): 84-94.
23	MILGROM S A, ELHALAWANI H, LEE J, et al. A PET radiomics model to predict refractory mediastinal Hodgkin lymphoma[J]. Sci Rep, 2019, 9(1): 1322.
24	LUE K H, WU Y F, LIU S H, et al. Prognostic value of pretreatment radiomic features of ¹⁸F-FDG PET in patients with Hodgkin lymphoma[J]. Clin Nucl Med, 2019, 44(10): e559-e565.
25	MAYERHOEFER M E, RIEDL C C, KUMAR A, et al. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2019, 46(13): 2760-2769.
26	LISSON C S, LISSON C G, MEZGER M F, et al. Deep neural networks and machine learning radiomics modelling for prediction of relapse in mantle cell lymphoma[J]. Cancers, 2022, 14(8): 2008.
27	WANG H X, ZHAO S N, LI L, et al. Development and validation of an ¹⁸F-FDG PET radiomic model for prognosis prediction in patients with nasal-type extranodal natural killer/T cell lymphoma[J]. Eur Radiol, 2020, 30(10): 5578-5587.
28	PARVEZ A, TAU N, HUSSEY D, et al. ¹⁸F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival[J]. Ann Nucl Med, 2018, 32(6): 410-416.
29	AIDE N, FRUCHART C, NGANOA C, et al. Baseline ¹⁸F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy[J]. Eur Radiol, 2020, 30(8): 4623-4632.
30	JIANG C, LI A, TENG Y, et al. Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2902-2916.
31	JIANG C, HUANG X J, LI A, et al. Radiomics signature from [¹⁸F]FDG PET images for prognosis predication of primary gastrointestinal diffuse large B cell lymphoma[J]. Eur Radiol, 2022, 32(8): 5730-5741.
32	EERTINK J J, VAN DE BRUG T, WIEGERS S E, et al. ¹⁸F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3): 932-942.
33	FROOD R, CLARK M, BURTON C, et al. Discovery of pre-treatment FDG PET/CT-derived radiomics-based models for predicting outcome in diffuse large B-cell lymphoma[J]. Cancers, 2022, 14(7): 1711.
34	ZHANG X H, CHEN L, JIANG H, et al. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [¹⁸F]FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2022, 49(4): 1298-1310.
35	COTTEREAU A S, NIOCHE C, DIRAND A S, et al. ¹⁸F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome[J]. J Nucl Med, 2020, 61(1): 40-45.
36	EERTINK J J, ZWEZERIJNEN G J C, CYSOUW M C F, et al. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features[J]. Eur J Nucl Med Mol Imaging, 2022, 49(13): 4642-4651.
37	JIMENEZ J E, DAI D, XU G F, et al. Lesion-based radiomics signature in pretherapy ¹⁸F-FDG PET predicts treatment response to ibrutinib in lymphoma[J]. Clin Nucl Med, 2022, 47(3): 209-218.
38	HU X B, GUO R, CHEN J N, et al. Coarse-to-fine adversarial networks and zone-based uncertainty analysis for NK/T-cell lymphoma segmentation in CT/PET images[J]. IEEE J Biomed Health Inform, 2020, 24(9): 2599-2608.
39	GUO R, HU X B, SONG H M, et al. Weakly supervised deep learning for determining the prognostic value of ¹⁸F-FDG PET/CT in extranodal natural killer/T cell lymphoma, nasal type[J]. Eur J Nucl Med Mol Imaging, 2021, 48(10): 3151-3161.

[1]	后书敏, 邵静波. TdT阴性的淋巴母细胞淋巴瘤/急性淋巴细胞白血病临床特点、诊断及预后研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(1): 120-124.
[2]	胡泽玉, 周铖, 杨林, 马晓燕, 肖海娟, 司海龙. 单形性嗜上皮性肠T细胞淋巴瘤致反复消化道出血1例[J]. 上海交通大学学报（医学版）, 2023, 43(1): 132-136.
[3]	姜正麟, 高云鸽, 吴皓. B细胞淋巴瘤/白血病11B在小鼠耳蜗螺旋器发育中的表达研究[J]. 上海交通大学学报（医学版）, 2022, 42(10): 1361-1374.
[4]	何俊林, 路青, 徐昕, 胡曙东. CT影像组学特征预测甲状腺乳头状癌颈部淋巴结转移的价值研究[J]. 上海交通大学学报(医学版), 2021, 41(9): 1233-1239.
[5]	刘子豪, 唐文芳, 王辉. 儿童脑肿瘤氨基酸PET显像的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(7): 949-952.
[6]	童桐, 秦星, 谢非, 蒋英英, 石剑波, 张建军. USP47通过促进抗凋亡蛋白表达介导头颈鳞癌细胞顺铂耐药[J]. 上海交通大学学报(医学版), 2021, 41(4): 434-441.
[7]	李高扬, 姜霁峰, 刘传绪, 张文皓, 朱杨, 马玉杰, 陶荣. 安罗替尼治疗难治性自然杀伤/T细胞淋巴瘤的有效性与安全性的探索性研究[J]. 上海交通大学学报(医学版), 2021, 41(2): 196-201.
[8]	倪雪萍1, 2，李贤华2，忻笑2，吴圣佳1, 2，宋婷1，赫洋2，郑欣2. 非霍奇金淋巴瘤患者自我感受负担现状及相关因素分析[J]. 上海交通大学学报(医学版), 2020, 40(6): 856-862.
[9]	姜涛 1, 2，施晴 1，许彭鹏 1，程澍 1，王黎 1，赵维莅 1. 肾上腺淋巴瘤临床病理特点及预后因素分析[J]. 上海交通大学学报（医学版）, 2019, 39(9): 1032-.
[10]	王佳琳，季迪，陈祥，杨博，余林. miR-218-2-3P靶向SIN3A基因影响NK/T细胞淋巴瘤的增殖和凋亡[J]. 上海交通大学学报（医学版）, 2019, 39(12): 1394-.
[11]	谢微 1，江旭峰 2，赵维莅 1，王黎 1. PET/CT不同判读方法对霍奇金淋巴瘤及弥漫大 B细胞淋巴瘤的预后评估作用[J]. 上海交通大学学报（医学版）, 2018, 38(8): 954-.
[12]	李高扬，姜霁峰，刘传绪，陶荣 . 藤黄酸抗 NK/T 细胞淋巴瘤作用的研究[J]. 上海交通大学学报（医学版）, 2017, 37(6): 738-.
[13]	赵冰冰,张慕晨,郝杰,刘振宇,熊红,赵维莅,王黎 . ICE治疗84例复发难治性弥漫大B细胞淋巴瘤的疗效及预后分析[J]. 上海交通大学学报（医学版）, 2017, 37(6): 752-.
[14]	孙漪峰许彭鹏赵维莅. T细胞淋巴瘤长链非编码RNA ST20-AS1的表达及其生物学作用[J]. 上海交通大学学报（医学版）, 2016, 36(9): 1265-.
[15]	肖慧芳郝杰赵维莅王黎. 非霍奇金淋巴瘤合并噬血细胞综合征的临床与预后分析[J]. 上海交通大学学报（医学版）, 2016, 36(8): 1187-.

¹⁸F-FDG PET/CT影像组学应用于淋巴瘤诊疗及预后预测的研究进展

Advances in the application of ¹⁸F-FDG PET/CT radiomics for diagnosis, treatment and prognosis prediction of lymphoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 15

编辑推荐

Metrics